{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-099708","form_type":"8-K/A","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2023-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.964253+00:00","generated_at":"2026-06-10T21:40:00.799520+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Ironwood files audited VectivBio financials: 2022 net loss $94M, 2021 & 2022 restated","bullets":["VectivBio 2022 revenue $27.3M from Asahi Kasei partner deal; net loss $94.1M.","VectivBio held $221.4M cash at Dec 31, 2022; total assets $252.6M.","Restated 2021 and 2022 statements to correct a misstatement; no further details here.","Pro forma combined results for Ironwood + VectivBio for H1 2023 and FY2022 included in filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-099708","json":"https://secwatch.observer/filing/0001104659-23-099708.json","markdown":"https://secwatch.observer/filing/0001104659-23-099708.md","text":"https://secwatch.observer/filing/0001104659-23-099708.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923099708/0001104659-23-099708-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923099708/tm2325734d1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T21:40:00.799520+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}